[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Vor Biopharma\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":72},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100551168","phase-3-a-study-of-telitacicept-for-the-treatment-of-generalized-myasthenia-gravis-upstream-mg-100551168",false,"NCT06456580","A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study With an Open-label Extension Period to Evaluate the Efficacy and Safety of Telitacicept in Patients With Generalized Myasthenia Gravis","Key Inclusion Criteria:\n\n1. Male or female patient aged ≥18 years at screening.\n2. Patients have prior confirmed diagnosis of gMG with generalized muscle weakness (typical pattern of weakness meeting the clinical criteria for diagnosis of MG as defined by the Myasthenia Gravis Foundation of America (MGFA) clinical classification II-IV.\n3. Patients have positive antibodies against AChR or MuSK at screening.\n4. MG-ADL score ≥6 points at screening and baseline with ocular-related score \\\u003C50% of the total score.\n5. QMG score ≥8 points, and ≥ 4 items score at least 2 points at screening and baseline.\n\nKey Exclusion Criteria:\n\n1. Patients have been diagnosed with any other autoimmune disease which can potentially pose a safety or efficacy confounding risk.\n2. Patients having acute or chronic infection.\n3. Patients having thymoma within 5 years or received thymectomy ≤6 months prior to screening. Patients with thymoma diagnosed 3-5 years prior to screening may be eligible if thymoma was at a localized stage and definitively treated with complete surgical resection.\n4. Patients having current or history of primary immunodeficiency.\n5. Patients having history of malignancy within the last 5 years.\n6. Patient having prior or continuing diagnosis of serious cardiovascular, liver, kidney, respiratory system, endocrine or hematologic disease.","ALL","18 Years",{"count":19,"type":20},180,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of generalized myasthenia gravis.",[26],"Generalized Myasthenia Gravis",[28,29],"Myasthenia Gravis","gMG","RECRUITING","2026-06-16",{"date":33,"type":34},"2026-06-18","ACTUAL",{"date":36,"type":34},"2024-07-17",{"date":38,"type":20},"2029-01",{"name":40,"class":41},"Vor Biopharma","INDUSTRY",111,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":70,"locationsCount":71},"100624071","phase-3-phase-3-study-of-telitacicept-in-active-primary-sjgrens-disease-100624071","NCT07404865","Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Telitacicept in Adult Participants With Active Primary Sjögren's Disease","UPSTREAM SjD","Inclusion Criteria:\n\n1. Male or female aged 18 to 75 years of age (both inclusive) at screening\n2. Participants must meet the 2016 American College of Rheumatology (ACR)\u002FEULAR classification criteria for primary Sjogren's Syndrome at the time of screening.\n3. ESSDAI ≥5 at screening (score calculated excluding renal, pulmonary and neurological domains)\n4. Participants are seropositive for antibodies to Sjogren's Syndrome A (SSA)\u002FAnti-Sjogren's Syndrome A (Ro) at the Screening Visit.\n\nAdditional inclusion criteria are defined in the protocol\n\nExclusion Criteria:\n\n1. Participants who have a systemic autoimmune disease other than Primary Sjogren's Disease, such as rheumatoid arthritis, systemic lupus erythematosus, or systemic sclerosis, that can better explain the majority of the symptoms (i.e., secondary Sjogren's Disease)\n2. Participants who have another autoimmune disease or inflammatory condition that could interfere with assessment of response of Primary Sjogren's Disease to therapy (e.g., systemic sclerosis, inflammatory bowel disease, gout).\n3. Participants with severe fibromyalgia that could interfere with the assessment of response of Primary Sjogren's Disease to therapy\n4. Active life-threatening or organ-threatening complications of Primary Sjogren's Disease at the time of screening based on investigator evaluation\n5. Significant, uncontrolled medical disease in any organ system not related to Primary Sjogren's Disease (e.g., poorly controlled asthma, cardiovascular disease, accelerated hypertension, major depression, etc.) that in the opinion of the investigator would preclude participant participation.\n\nAdditional exclusion criteria are defined in the protocol","75 Years",{"count":53,"type":20},250,[23],"Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease (UPSTREAM SjD)",[57],"Primary Sjogren's Disease",[59,60,61,62,63],"Sjögren's Disease","pSD","Primary Sjogren's Syndrome","Sjogren's Syndrome","SjD","2026-06-02",{"date":66,"type":34},"2026-06-04",{"date":68,"type":34},"2026-02-26",{"date":38,"type":20},{"name":40,"class":41},26,""]